208 related articles for article (PubMed ID: 26438158)
21. Combining inotuzumab ozogamicin with PARP inhibitors olaparib and talazoparib exerts synergistic cytotoxicity in acute lymphoblastic leukemia by inhibiting DNA strand break repair.
Ida N; Okura M; Tanaka S; Hosono N; Yamauchi T
Oncol Rep; 2024 Jul; 52(1):. PubMed ID: 38785163
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
23. Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA.
Heinicke U; Fulda S
Cancer Lett; 2014 Aug; 351(1):50-8. PubMed ID: 24814395
[TBL] [Abstract][Full Text] [Related]
24. Pyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin B-dependent and caspase-dependent apoptotic pathways.
Dai C; Zhang B; Liu X; Guo K; Ma S; Cai F; Yang Y; Yao Y; Feng M; Bao X; Deng K; Jiao Y; Wei Z; Junji W; Xing B; Lian W; Wang R
Int J Cancer; 2013 Oct; 133(8):1982-93. PubMed ID: 23564480
[TBL] [Abstract][Full Text] [Related]
25. Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells.
McDonald ES; Mankoff J; Makvandi M; Chu W; Chu Y; Mach RH; Zeng C
Biochem Biophys Res Commun; 2017 May; 486(3):788-795. PubMed ID: 28347815
[TBL] [Abstract][Full Text] [Related]
26. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
[TBL] [Abstract][Full Text] [Related]
27. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Murai J; Huang SY; Renaud A; Zhang Y; Ji J; Takeda S; Morris J; Teicher B; Doroshow JH; Pommier Y
Mol Cancer Ther; 2014 Feb; 13(2):433-43. PubMed ID: 24356813
[TBL] [Abstract][Full Text] [Related]
28. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).
Schafer ES; Rau RE; Berg SL; Liu X; Minard CG; Bishop AJR; Romero JC; Hicks MJ; Nelson MD; Voss S; Reid JM; Fox E; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2020 Feb; 67(2):e28073. PubMed ID: 31724813
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Tentori L; Leonetti C; Scarsella M; Muzi A; Mazzon E; Vergati M; Forini O; Lapidus R; Xu W; Dorio AS; Zhang J; Cuzzocrea S; Graziani G
FASEB J; 2006 Aug; 20(10):1709-11. PubMed ID: 16809434
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy: The role of ifosfamide and etoposide in Ewing sarcoma.
DuBois SG; Grier HE
Nat Rev Clin Oncol; 2009 May; 6(5):251-3. PubMed ID: 19390548
[TBL] [Abstract][Full Text] [Related]
31. Synergistic Effects of Olaparib and DNA-damaging Agents in Oesophageal Squamous Cell Carcinoma Cell Lines.
Miyamoto K; Minegaki T; Tanahashi M; Yamamoto A; Moriyama Y; Wada A; Matsumoto A; Ota K; Tanaka M; Masuda U; Tsujimoto M; Nishiguchi K
Anticancer Res; 2019 Apr; 39(4):1813-1820. PubMed ID: 30952721
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.
Choy E; Butrynski JE; Harmon DC; Morgan JA; George S; Wagner AJ; D'Adamo D; Cote GM; Flamand Y; Benes CH; Haber DA; Baselga JM; Demetri GD
BMC Cancer; 2014 Nov; 14():813. PubMed ID: 25374341
[TBL] [Abstract][Full Text] [Related]
33. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
34. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma.
Heske CM; Davis MI; Baumgart JT; Wilson K; Gormally MV; Chen L; Zhang X; Ceribelli M; Duveau DY; Guha R; Ferrer M; Arnaldez FI; Ji J; Tran HL; Zhang Y; Mendoza A; Helman LJ; Thomas CJ
Clin Cancer Res; 2017 Dec; 23(23):7301-7311. PubMed ID: 28899971
[No Abstract] [Full Text] [Related]
35. Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition.
Mattoo AR; Joun A; Jessup JM
Mol Cancer Res; 2019 Jan; 17(1):42-53. PubMed ID: 30201826
[TBL] [Abstract][Full Text] [Related]
36. PARP inhibition in UV-associated angiosarcoma preclinical models.
Weidema ME; Desar IME; Hillebrandt-Roeffen MHS; van Erp AEM; Masuzawa M; ; Flucke UE; van der Graaf WTA; Versleijen-Jonkers YMH
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2579-2590. PubMed ID: 34085099
[TBL] [Abstract][Full Text] [Related]
37. Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
Sampson VB; Vetter NS; Kamara DF; Collier AB; Gresh RC; Kolb EA
PLoS One; 2015; 10(11):e0142704. PubMed ID: 26571493
[TBL] [Abstract][Full Text] [Related]
38. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
Martins AS; Mackintosh C; Martín DH; Campos M; Hernández T; Ordóñez JL; de Alava E
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3532-40. PubMed ID: 16740780
[TBL] [Abstract][Full Text] [Related]
39. Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Lesueur P; Lequesne J; Grellard JM; Dugué A; Coquan E; Brachet PE; Geffrelot J; Kao W; Emery E; Berro DH; Castera L; Goardon N; Lacroix J; Lange M; Capel A; Leconte A; Andre B; Léger A; Lelaidier A; Clarisse B; Stefan D
BMC Cancer; 2019 Mar; 19(1):198. PubMed ID: 30832617
[TBL] [Abstract][Full Text] [Related]
40. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]